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Pediatric tuberculosis (TB) is an underappreciated problem and accounts for 10 % of all TB deaths worldwide.
Children are highly susceptible to infection with Mycobacterium tuberculosis and interrupting TB spread would
require the development of effective strategies to control TB transmission in pediatric populations. The current
vaccine for TB, M. bovis Bacille Calmette-Guérin (BCG), can afford some level of protection against TB meningitis and
severe forms of disseminated TB in children; however, its efficacy against pulmonary TB is variable and the vaccine
does not afford life-long protective immunity. For these reasons there is considerable interest in the development
of new vaccines to control TB in children. Multiple vaccine strategies are being assessed and include recombinant
forms of the existing BCG vaccine, protein or viral candidates designed to boost BCG-induced immunity, or live
attenuated forms of M. tuberculosis. A number of these candidates have entered clinical trials; however, no vaccine
has shown improved protective efficacy compared to BCG in humans. The current challenge is to identify the most
suitable candidates to progress from early to late stage clinical trials, in order to deliver a vaccine that can control
and hopefully eliminate the global threat of TB.
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Tuberculosis (TB), caused by the intracellular bacterial
pathogen Mycobacterium tuberculosis, remains a major
cause of mortality and morbidity worldwide. Annually
there are an estimated 9.6 million new cases of clinical
TB and 1.5 million deaths, the majority occurring in
South-East Asia [1]. The spread of TB is fueled by the
human immunodeficiency virus (HIV)/acquired immune
deficiency syndrome (AIDS) pandemic, the emergence
of multi-drug resistant strains and socio-political disrup-
tion to health services. TB is a chronic infection and is
generally considered a diseases of adulthood, however
pediatric TB is an underappreciated problem. Infants
under the age of two have the highest risk of contracting
TB [2]. One million children contracted TB in 2014 and
approximately 10 % of all TB deaths were in children
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vere forms of pediatric TB, but its efficacy is variable,
particularly against pulmonary disease in infants and
adults. This review discusses the novel strategies being
used to develop new TB vaccines, provides an overview
of the candidates in clinical trials and outlines the chal-
lenges of introducing a new TB vaccine into existing
childhood vaccination schedules.Vaccination against TB: the current state of play
BCG, an attenuated live form of M. bovis, has been in
use since the early 1920s and is the only approved vac-
cine for the control of TB in humans. BCG can afford
some level of protection, particularly against TB menin-
gitis and severe forms of disseminated TB in children
[3]. In a case-controlled trial in Argentina to determine
the efficacy of BCG vaccination against TB in children
under the age of 6, the vaccine afforded 98 % protection
against TB meningitis and miliary TB [4]. Meta-analysis
of trial data showed that BCG could prevent 73 % of
childhood TB meningitis and 77 % of miliary TB cases
disease in children [5]. However, BCG affords variable
efficacy against pulmonary TB, the predominant form ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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[6]. Recent analysis suggests that BCG can, to some ex-
tent, protect against initial infection with M. tubercu-
losis, however this only occurs in a small proportion of
exposed individuals [7]. Compounding this is the evi-
dence from field trials that protective immunity afforded
by BCG is not lifelong and wanes 10–15 years after vac-
cination [3]. Considering that TB is a chronic disease
where more than 90 % of cases are in adolescents and
adults, the limited longevity of the vaccine’s protective
effect is a significant barrier to TB control.
TB is a complex disease and M. tuberculosis has exquis-
itely adapted to life within the infected host. The disease is
characterized by a latent phase, where the organism exists
in a form that evades immune clearance, yet is unable to
cause active disease [8]. An estimated 2 billion individuals
are latently infected with M. tuberculosis, representing an
enormous reservoir who may reactivate TB later in life. In
humans and in animal models, BCG is unable to reduce
latent infection and/or prevent reactivation, and as such
the development of vaccines that can target latent bacteria
would be a significant advance. In addition, new vaccines
should induce the type of immunity proposed to protect
against M. tuberculosis infection. As an obligate intracellu-
lar pathogen, a cell-mediated T-cell response is required
to contain and ideally eliminate bacteria within infected
host cells ([9], Fig. 1). The generation of ‘Th1-like’ CD4+
T-cell secreting multiple cytokines are considered to be
those required for optimal protective immunity, and most
vaccines aim to generate these T-cells at high frequency.
In order to address the deficiencies of BCG, multiple
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Fig. 1 Vaccine-induced immunity to mycobacteria. Dendritic cells (DCs) are
pattern recognition receptors (PRRs), which leads to the presentation of pe
cell subsets are associated with protective responses in animal models of M
host cells such as macrophages (MAC) to eliminate ingested bacteria. Cyto
of memory T-cell populations (Tmem). Although B cells may be stimulated
in protection against mycobacteria and are not typically a target of rationacandidates. These include boosting BCG-induced immun-
ity, modifying the existing BCG vaccine to improve its ef-
fectiveness, or replacing BCG with improved live vaccine
candidates. The remainder of this review will describe the
current TB vaccine candidates that have advanced to clin-
ical trials, including those developed to prevent TB in
children.
Boosting BCG: subunit vaccines M. tuberculosis
antigens
It is likely that BCG will remain part of current vaccine
schedules, considering its good safety profile and its effect-
iveness against severe childhood forms of TB. For this rea-
son there is particular interest in the development of
subunit vaccines composed of protective M. tuberculosis
antigens, as these may be used to ‘boost’ the protective re-
sponse developed by BCG. A handful of vaccines have
now entered clinical trials [10], however most of these
vaccines make use of a small subset of related secreted an-
tigens. This is despite the fact that M. tuberculosis ex-
presses literally hundreds of antigenic targets, including
non-secreted proteins [11] and no single mycobacterial
antigen is recognised by all M. tuberculosis-infected indi-
viduals [12–14]. For this reason, all protein vaccines in
clinical trials encode multiple antigens to expand the im-
mune recognition of the vaccine (Table 1). In addition, the
method of subunit protein delivery is critical for vaccine
efficacy and considerable effort has been expended on the
identification of potent adjuvants that are nevertheless
sufficiently safe and well tolerated for human use [15].
The most advanced fusion protein candidate in terms














activated by vaccine components, such as adjuvants engaging
ptide fragments to CD8+ and CD4+ T-cells. Both Th1 and Th17 CD4+ T-
. tuberculosis infection, in particular through the stimulation of infected
kines (e.g. IL-2) secreted by Th1 CD4+ T-cells promote the maintenance
to produce antibody upon vaccination, they appear to have little role
lly designed vaccines
Table 1 Tuberculosis vaccine candidates in clinical trials
Category Vaccine Clinical trial
stage
Trials in childrena Vaccine Description
Subunit – protein in
adjuvant
M72/AS01 Phase IIb NCT01098474 (Phase II) Fusion protein (Mtb39a, Mtb32a) in AS01 adjuvant
H1/IC31 Phase IIa Fusion protein (Ag85B, ESAT-6) in IC31 adjuvant
H4/IC31 Phase II NCT01861730 (Phase I/II) Fusion protein (Ag85B, TB10.4) in IC31 adjuvant
H56/IC31 Phase IIa Fusion protein (Ag85B, ESAT-6, Rv2660c) in IC31 adjuvant




MVA85A Phase IIb NCT00953927 (Phase IIb) Replication-deficient vaccinia Ankara virus expressing
Ag85A
Ad5Ag85A Replication-deficient adenovirus-5 expressing Ag85A
AD35.TB-S NCT01198366 (Phase II) Replication-defective adenovirus-35 expressing Ag85A,
Ag85B, TB10.4
Recombinant BCG rBCG30 Phase I
(discontinued)
Recombinant BCG over-expressing Ag85B
VPM1002 Phase IIa NCT01479972 (Phase I)
NCT02391415 (Phase IIa)




Recombinant BCG expressing Ag85A, Ag85B, Rv3407
Attenuated M.
tuberculosis




Dar-901 Phase I Heat-inactivated Mycobacterium obuense
a Clinical trial identifier as taken from www.clinicaltrials.gov
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Mtb32a, delivered in the AS01 adjuvant, which includes
the immune-stimulants 3-O-desacyl-4′-monophosphoryl
lipid A (MPL) and Quillaja saponaria fraction 1 (QS21)
combined with liposomes (AS01) [16, 17]. In a Phase I/
II trial the vaccine was well tolerated and induced high
levels of polyfunctional M72-specific CD4+ T-cell and
persistent antibody responses [17]. Numerous Phase II
trials in adolescents [18], adults [19] or BCG-vaccinated
infants [20] demonstrated the generation of polyfunc-
tional CD4+ T-cells, augmented humoral responses and
no adverse events associated with the vaccine. Import-
antly, immune responses and vaccine safety were not al-
tered when the vaccine was delivered to infants together
with Expanded-Programme-on-Immunization (EPI) vac-
cines [20]. The vaccine was shown to retain immuno-
genicity in HIV+ subjects on anti-retroviral therapy [21]
and has recently entered a Phase IIb proof of concept ef-
ficacy study in latently-infected adults (ClinicalTrials.gov
Identifier: NCT01755598).
A number of fusion protein vaccines, based on the se-
creted Ag85B protein of M. tuberculosis, are currently
under evaluation in humans. Hybrid 1/IC31 comprises
Ag85B fused with the early secretory antigenic target 6
(ESAT6), an immunogenic antigen absent from BCG
[22]. The fusion protein is adjuvanted with IC31, a 2-
component adjuvant comprising an 11-mer antibacterial
peptide (KLK) and a synthetic oligodeoxynucleotide(ODN1a), a Toll-like receptor 9 agonist [23]. In Phase I
and II trials the vaccine has demonstrated strong, sus-
tained generation of T-cell responses in naïve volunteers
[24], individuals previously BCG vaccinated/M. tubercu-
losis infected [25] and HIV+ individuals [26]. Hybrid 4/
IC31 (AERAS-404) includes the TB10.4 antigen instead
of ESAT-6, due to the latter being a component of the
Quantiferon Gold diagnostic test for M. tuberculosis in-
fection. Hybrid 4/IC31 induced persistent polyfunctional
CD4+ T-cell responses in adults [27] and the vaccine’s
ability to prevent infection with M. tuberculosis in ado-
lescents is currently under evaluation (NCT02075203).
Hybrid 56/IC31 (AERAS-456) is a modified version of
Hybrid 1 that includes Rv2660c, an antigen strongly rec-
ognized by the immune response of latent TB patients
[28]. The vaccine was shown to protect non-human pri-
mates against reactivation of latent M. tuberculosis infec-
tion [29] and was immunogenic when delivered to
healthy adults with or without previous M. tuberculosis
infection [30]. An ongoing Phase I trial will assess the
safety and immunogenicity of Hybrid 56/IC31 in HIV-
negative subjects recently treated for drug-susceptible
pulmonary TB (NCT02375698) and in BCG-primed in-
fants (NCT01861730).
ID93/GLA-SE is a fusion of four unique antigens
(Rv2608, Rv3619, Rv1813, Rv3620) identified during a
screen for human anti-mycobacterial T-cell antigens
[31]. The vaccine is formulated with the TLR adjuvant
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and has shown good protective efficacy in a number of
pre-clinical animal models, including mice and guinea
pigs, with the generation of polyfunctional T-cell subsets
[32]. No clinical data on ID93/GLA-SE has been re-
ported; however, the vaccine is undergoing safety/im-
munogenicity testing in healthy volunteers (Phase I,
NCT01599897, NCT01927159) and in patients following
successful completion of TB treatment (NCT02465216).
Boosting BCG: recombinant viral vectors
Viral vectors have been extensively studied as vaccines to
control many pathogens, due to their ability to induce ro-
bust cellular and humoral immune responses [33]. The
eradication of smallpox by the vaccinia virus has focused at-
tention on the use of poxviruses as vaccine vectors, in par-
ticular modified vaccinia virus Ankara (MVA) [33].
MVA85A (AERAS-485), in which the M. tuberculosis
Ag85A protein is expressed by MVA, was the first TB vac-
cine to enter human trials [34]. The vaccine, which has
been tested in multiple Phase I/IIa studies in adults, adoles-
cents, children and infants, was shown to be well tolerated
and induce diverse vaccine-specific T-cell responses [35].
However, in a Phase IIb efficacy trial to test a BCG-prime,
MVA85A-boost regimen in BCG-vaccinated South African
infants, the vaccine did not provide improved protective ef-
ficacy against M. tuberculosis infection or disease [36]. An
additional Phase IIb trial assessing the efficacy in healthy
adults infected with HIV in South Africa and Senegal dem-
onstrated significant T-cell responses induced by the vac-
cine but there was no improved efficacy against M.
tuberculosis infection or disease in the MVA85A group
compared to placebo [37]. Although the consistency of the
pre-clinical animal data supporting this vaccine has been
questioned [38], the vaccine has been instrumental in the
development of large-scale clinical efficacy trials of vaccines
against TB and developing protocols for defining correlates
of TB vaccine-induced protection in humans [35].
Replication-deficient adenoviral vectors are an additional
class of vaccine vectors that are being utilised for recom-
binant antigen delivery [33]. AdAg85A is an adenoviral
serotype 5 vector expressing the M. tuberculosis Ag85A
protein. In preclinical animal models the vaccine provided
optimal protective efficacy when delivered mucosally, in
particular the boosting of prior BCG immunization [39].
The vaccine has been tested in humans after intramuscular
delivery, however the study was terminated for undefined
reasons (NCT00800670). One important issue with adeno-
viral vectors is the observation that pre-existing Ad5 anti-
bodies have been shown to correlate with Ad5-based HIV
vaccine failure [40]. However, infants appear to have re-
duced levels of neutralizing Ad5 antibodies, which suggests
these vaccines may be more suitable for pediatric popula-
tions [41]. Pre-existing vector-specific immunity has beenovercome by use of chimpanzee adenoviruses (ChAds),
with a number of ChAds in clinical trials [33]. This includes
a ChAd vector expressing M. tuberculosis Ag85A (ChA-
dOx185A), which is being assessed together with a
MVA85A boost in adults (NCT01829490). AD35.TB-S
(AERAS-402) is a replication-deficient serotype 35 adeno-
virus that encodes a fusion of 3M. tuberculosis (Ag85A,
Ag85B, TB10.4) and has been assessed in BCG-vaccinated
infants and adults, as well as HIV+ individuals [42–44]. The
vaccine induced polyfunctional CD4+/CD8+ T-cell and
antibody responses to the encoded vaccine antigens, yet in-
duced a modest level of Ad35 antibodies [42–44].Improving BCG: recombinant forms of BCG
Despite the limitations of BCG described above, the vac-
cine does induce some level of protection against child-
hood forms of TB, and BCG vaccination can reduce
mortality in children due to other diseases [45]. There-
fore, a major focus of TB vaccine development programs
is the development of modified forms of BCG to im-
prove the protective efficacy of the vaccine (reviewed in
[46]). Of the numerous recombinant BCG strains devel-
oped, only three have undergone human trials. rBCG30,
which overexpresses the immunodominant Ag85B pro-
tein, demonstrated improved efficacy in M. tuberculosis-
infected guinea pigs, in terms of reduced bacterial loads
and improved survival compared to BCG-only vacci-
nated animals [47]. Although the vaccine was demon-
strated to be safe and immunogenic in a Phase I clinical
trial in adults, the vaccine is not being pursued further
[48]. An alternative strategy was taken in the develop-
ment of VPM1002, a recombinant BCG expressing the
Listeria monocytogenes enzyme listeriolysin O (LLO) and
deleted of the ureC gene, in order to facilitate LLO func-
tion. Listeriolysin perforates the phagosomal membrane,
allowing leakage of enzymes and bacterial components into
the cytoplasm and increased apoptosis of the infected cell,
resulting in enhanced CD4+ and CD8+ T-cell responses
[49]. The vaccine candidate has completed a Phase I trial in
infants (NCT01479972), and is currently being assessed for
safety and immunogenicity in HIV-exposed newborns
(ClinicalTrials.gov Identifier: NCT02391415).
A dual strategy of antigen overexpression and immune
modulation was employed in the development of
AERAS-422, a BCG strain expressing the pore-forming
perfringolysin of Clostridium perfringens and selected
immunodominant antigens expressed by M. tuberculosis
during active infection (Ag85A and Ag85B) and reactiva-
tion of latent infection (Rv3407) [50]. In a Phase I trial in
adults, the vaccine induced strong antigen-specific T-cell
responses; however, two of eight vaccinees developed vari-
cella zoster virus (VZV) reactivation, resulting in the dis-
continuation of the vaccine’s development [51].
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An alternative approach to TB vaccine design is to use live
mycobacterial strains to replace BCG in the childhood vac-
cine schedule. When compared to virulent M. tuberculosis
isolates, more than one hundred genes are absent in the
BCG genome [52], and a subset of these genes may be im-
portant protective antigens. Therefore, a rationally attenu-
ated form of M. tuberculosis may more closely ‘mimic’ the
immune repertoire generated by natural infection.
MTBVAC is the first live-attenuated M. tuberculosis-based
vaccine to undergo testing in humans. MTBVAC contains
two independent stable deletion mutations in the virulence
genes phoP and fadD26, without the inclusion of antibiotic
resistance markers, thus fulfilling the second Geneva Con-
sensus requirements for progression of live mycobacterial
vaccines to human trials [53, 54]. The vaccine afforded sig-
nificant protection against M. tuberculosis in pre-clinical
models [55] and induced markedly enhanced T-cell im-
munity compared to the BCG vaccine in mice [56]. In a
Phase I clinical trial MTBVAC did not induce any serious
adverse events and elicited the generation of polyfunctional
CD4+ central memory T-cells in vaccinees [57]. Encour-
agingly, vaccine safety and immunogenicity is currently be-
ing assessed in newborns in a Phase I trial (NCT02729571).
Inactivated whole-cell mycobacterial strains are also be-
ing assessed, although mainly as post-infection/immuno-
therapeutic vaccines, with the aim of preventing
reactivation and/or shortening the course of drug-
treatment for TB. The immunotherapeutic potential of
these vaccines has been reviewed elswehere [58] and will
not be discussed here. One inactivated vaccine, termed
Dar-901, is under evaluation as a preventative TB vaccine.
Dar-901 consists of the heat-inactivated non-tuberculous
M. obuense and is part of a Phase I clinical trial for safety
and immunogenicity healthy adults (NCT02063555), and is
currently recruiting for a Phase II trial as a booster to pre-
vent TB in adoloscents (NCT02712424).
Challenges of TB vaccine development
A number of challenges remain before a new vaccine can
be introduced to either complement or replace the exist-
ing BCG vaccine. Although there is an appreciation that
multiple antigens should be included into subunit vaccine
to broaden the immune response generated, many candi-
dates use single antigens—in particular Ag85A, which in a
recent study was not strongly recognized by the immune
response of TB patients [14]. Unlike viruses, which tend
express a limited number of antigenic targets, the antigen
repertoire of mycobacteria is broad and includes poorly
expressed and cryptic epitopes that may contribute to pro-
tection [59]. Therefore new vaccine candidates should
ideally express a selection of antigens that are strongly
recognised by the human immune response during allstages of the TB life cycle. In addition, assessment of anti-
gen immune recognition has typically been performed in
adult TB patients, rather than children [14] and it is pos-
sible that the infant immune system may display differen-
tial recognition of antigens. Compounding this is the fact
that most clinical trials of TB vaccine have been per-
formed in adolescent or adult populations (Table 1), thus
limiting our knowledge of vaccine-induced immunity in
children.
An additional consideration is the lack of defined im-
mune correlates of protection against M. tuberculosis in-
fection. Certain immune responses appear to correlate
with protection against M. tuberculosis in animal
models, such as CD4+ T-cell secreting mutiple cytokines,
termed ‘polyfunctional T’ cells [60]. However, the pres-
ence of polyfunctional T-cells in either MVA85A-
vaccinated adults or BCG-vaccinated infants did not cor-
relate with protection against TB in humans [36, 61].
While this may be a function of the particular vaccine
tested, it does suggest that a greater breadth of immune
paramaters should be examined as potential ‘biomarkers’
of protection, including non-conventional T-cells and
components of the innate immune response [9]. Import-
antly, while the mouse is the major animal model used
for testing of TB vaccines, the relative contribution of
immune cell subsets may differ between the mouse,
humans and other models such as non-human primates
[62]. This makes it difficult to extrapolate findings from
animal models to humans. While a human challenge
model for TB has been proposed [63], the curent model
relies on use of the attenuated BCG vaccine as the chal-
lenge organism, which lacks important TB vaccine anti-
gens, and further optimisation is required to overcome
the low level of recovery of the challenge strain [64].
However, such a model would provide an important tool
for TB vaccine research, considering the expense of large
phase IIb and phase III clinical trials to determine vac-
cine efficacy for a chronic infection such as TB, together
with the lack of markers of protective immunity in
humans.
Conclusions
The past decade has seen major advances in the develop-
ment of TB vaccines, with a number of vaccines now in
clinical trials (Table 1) and one vaccine having completed
Phase IIb assessment of efficacy [36]. However, no vaccine
has demonstrated improved protective efficacy in humans
compared to the existing BCG vaccine, and the immuno-
logical parameters required for effective protective efficacy
in humans are not known. This suggests that innovative
and novel TB vaccine approaches are required and these
vaccines should elicit immune responses that differ from
those candidates that have already been evaluated in
humans. Effective control of TB transmission will require
Triccas and Counoupas Pneumonia  (2016) 8:18 Page 6 of 7the delivery of a vaccine that can block/limit M. tubercu-
losis infection during initial exposure to the pathogen,
which in endemic areas would be during early childhood,
and thus the testing of new candidates in infant popula-
tions should be a priority.
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